Hepatic Veno-occlusive Disease (Sinusoidal Obstruction Syndrome) After Hematopoietic Stem Cell Transplantation

Willmot, 1920, Senecio disease, or cirrhosis of the liver due to Senecio poisoning, Lancet, 2, 848, 10.1016/S0140-6736(01)00020-4 DeLeve, 2002, Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease), Semin Liver Dis, 22, 27, 10.1055/s-2002-23204 Datta, 1978, Herbal medicines and veno-occlusive disease in India, Postgrad Med J, 54, 511, 10.1136/pgmj.54.634.511 Tandon, 1976, Study of an epidemic of venoocclusive disease in India, Gut, 17, 849, 10.1136/gut.17.11.849 Berk, 1979, Veno-occlusive disease of the liver after allogeneic bone marrow transplantation: possible association with graft-versus-host disease, Ann Intern Med, 90, 158, 10.7326/0003-4819-90-2-158 Jacobs, 1979, Fatal veno-occlusive disease of the liver after chemotherapy, whole-body irradiation and bone marrow transplantation for refractory acute leukaemia, S Afr Med J, 55, 5 McDonald, 1984, Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors, Hepatology, 4, 116, 10.1002/hep.1840040121 Shulman, 1980, An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation, Gastroenterology, 79, 1178, 10.1016/0016-5085(80)90911-7 Carreras, 1993, Hepatic veno-occlusive disease after bone marrow transplant, Blood Rev, 7, 43, 10.1016/0268-960X(93)90023-W Ortega, 1997, Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group, Cancer, 79, 2435, 10.1002/(SICI)1097-0142(19970615)79:12<2435::AID-CNCR21>3.0.CO;2-R Paschke, 1985, Pathophysiological aspects of dacarbazine-induced human liver damage, Hepatogastroenterology, 32, 273 Kao, 1993, 6-Thioguanine therapy for psoriasis causing toxic hepatic venoocclusive disease, J Am Acad Dermatol, 28, 1017, 10.1016/S0190-9622(08)80659-7 Read, 1986, Hepatic venoocclusive disease associated with renal transplantation and azathioprine therapy, Ann Intern Med, 104, 651, 10.7326/0003-4819-104-5-651 Giles, 2001, Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation, Cancer, 92, 406, 10.1002/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U Bisogno, 1997, Veno-occlusive disease of the liver in children treated for Wilms tumor, Med Pediatr Oncol, 29, 245, 10.1002/(SICI)1096-911X(199710)29:4<245::AID-MPO2>3.0.CO;2-M Sebagh, 1999, “Silent” presentation of veno-occlusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilection, Hepatology, 30, 1144, 10.1002/hep.510300514 McDonald, 1993, Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients, Ann Intern Med, 118, 255, 10.7326/0003-4819-118-4-199302150-00003 Shulman, 1992, Hepatic veno-occlusive disease—liver toxicity syndrome after bone marrow transplantation, Bone Marrow Transplant, 10, 197 Carreras, 1998, Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation, Blood, 92, 3599 Jones, 1987, Venoocclusive disease of the liver following bone marrow transplantation, Transplantation, 44, 778, 10.1097/00007890-198712000-00011 Shulman, 1994, Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms, Hepatology, 19, 1171, 10.1002/hep.1840190515 Shulman, 1987, Hepatic veno-occlusive disease after bone marrow transplantation: immunohistochemical identification of the material within occluded central venules, Am J Pathol, 127, 549 DeLeve, 1999, Characterization of a reproducible rat model of hepatic veno-occlusive disease, Hepatology, 29, 1779, 10.1002/hep.510290615 McCuskey, 1993, Hepatic microvasculature: dynamic structure and its regulation, Semin Liver Dis, 13, 1, 10.1055/s-2007-1007333 McCuskey, 2000, Morphological mechanisms for regulating blood flow through hepatic sinusoids, Liver, 20, 3, 10.1034/j.1600-0676.2000.020001003.x Harper, 1990, Changes in the natural anticoagulants following bone marrow transplantation, Bone Marrow Transplant, 5, 39 Scrobohaci, 1991, Liver venoocclusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers, Thromb Res, 63, 509, 10.1016/0049-3848(91)90176-W Vannucchi, 1994, Early hemostatic alterations following bone marrow transplantation: a prospective study, Haematologica, 79, 519 Faioni, 1997, Venocclusive disease of the liver after bone marrow transplantation: the role of hemostasis, Leuk LymphomA, 25, 233, 10.3109/10428199709114163 Catani, 1993, Hypercoagulability in patients undergoing autologous or allogeneic BMT for hematological malignancies, Bone Marrow Transplant, 12, 253 Collins, 1992, von Willebrand factor as a marker of endothelial cell activation following BMT, Bone Marrow Transplant, 10, 499 Testa, 1996, Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation, Bone Marrow Transplant, 18, 383 Catani, 1996, Endothelium and bone marrow transplantation, Bone Marrow Transplant, 17, 277 Holler, 1990, Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation, Blood, 75, 1011, 10.1182/blood.V75.4.1011.1011 Bianco, 1991, Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation [published correction appears in Blood. 1992;79:3397], Blood, 78, 1205, 10.1182/blood.V78.5.1205.1205 Soiffer, 1991, Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation, Transplantation, 52, 1014, 10.1097/00007890-199112000-00015 Sato, 1999, Hepatic stellate cells (Ito cells) in veno-occlusive disease of the liver after allogeneic bone marrow transplantation, Histopathology, 34, 66, 10.1046/j.1365-2559.1999.00569.x Ayash, 1990, Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas, J Clin Oncol, 8, 1699, 10.1200/JCO.1990.8.10.1699 Frickhofen, 1994, Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation, Blood, 83, 1998, 10.1182/blood.V83.7.1998.1998 Locasciulli, 1999, The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group, Transplantation, 68, 1486, 10.1097/00007890-199911270-00010 Strasser, 1999, Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up, Hepatology, 29, 1893, 10.1002/hep.510290609 Faioni, 1993, Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver, Blood, 81, 3458, 10.1182/blood.V81.12.3458.3458 Ertem, 2000, Factor V Leiden mutation as a predisposing factor for veno-occlusive disease following BMT [letter], Bone Marrow Transplant, 25, 1110, 10.1038/sj.bmt.1702390 Duggan, 1999, The prothrombin gene variant G20210A but not factor V Leiden may be associated with veno-occlusive disease following BMT [letter], Bone Marrow Transplant, 24, 693, 10.1038/sj.bmt.1701952 Hägglund, 1998, Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation, Blood, 92, 4568, 10.1182/blood.V92.12.4568 Deeg, 1986, Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation, Bone Marrow Transplant, 1, 151 Ringden, 1994, A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group, Blood, 83, 2723, 10.1182/blood.V83.9.2723.2723 Gluckman, 1990, Role of PGE1 to prevent veno-occlusive disease of the liver after bone marrow transplantation, Nouv Rev Fr Hematol, 32, 1 DeLeve, 1996, Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation, Hepatology, 24, 830, 10.1002/hep.510240414 Teicher, 1988, Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide, Cancer, 62, 1275, 10.1002/1097-0142(19881001)62:7<1275::AID-CNCR2820620705>3.0.CO;2-I DeLeve, 1990, Importance and regulation of hepatic glutathione, Semin Liver Dis, 10, 251, 10.1055/s-2008-1040481 DeLeve, 1998, Glutathione defense in non-parenchymal cells, Semin Liver Dis, 18, 403, 10.1055/s-2007-1007173 DeLeve, 2000, Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes, Pharmacology, 60, 143, 10.1159/000028359 Wang, 2000, Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat, Hepatology, 31, 428, 10.1002/hep.510310224 Meresse, 1992, Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children, Bone Marrow Transplant, 10, 135 Grochow, 1989, Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation, Cancer Chemother Pharmacol, 25, 55, 10.1007/BF00694339 Grochow, 1993, Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens, Semin Oncol, 20, 18 Carreras, 2000, Veno-occlusive disease of the liver after hemopoietic cell transplantation, Eur J Haematol, 64, 281, 10.1034/j.1600-0609.2000.9r200.x Rozman, 1996, Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia, Bone Marrow Transplant, 17, 75 Essell, 1992, Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide, Blood, 79, 2784, 10.1182/blood.V79.10.2784.2784 Bearman, 1995, The syndrome of hepatic veno-occlusive disease after marrow transplantation, Blood, 85, 3005, 10.1182/blood.V85.11.3005.bloodjournal85113005 Toh, 1999, Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation, Bone Marrow Transplant, 24, 891, 10.1038/sj.bmt.1701994 Bearman, 1993, Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation, J Clin Oncol, 11, 1729, 10.1200/JCO.1993.11.9.1729 Rio, 1986, Thrombocytopenia in venocclusive disease after bone marrow transplantation or chemotherapy, Blood, 67, 1773, 10.1182/blood.V67.6.1773.1773 Matute-Bello, 1998, Association of pulmonary function testing abnormalities and severe veno-occlusive disease of the liver after marrow transplantation, Bone Marrow Transplant, 21, 1125, 10.1038/sj.bmt.1701225 Wingard, 1989, Association of hepatic veno-occlusive disease with interstitial pneumonitis in bone marrow transplant recipients, Bone Marrow Transplant, 4, 685 Carreras, 1993, On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease, Ann Hematol, 66, 77, 10.1007/BF01695888 Lassau, 1997, Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients, Radiology, 204, 545, 10.1148/radiology.204.2.9240551 van den Bosch, 2000, MR imaging findings in two patients with hepatic veno-occlusive disease following bone marrow transplantation, Eur Radiol, 10, 1290, 10.1007/s003300000330 Shulman, 1995, Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients, Transplantation, 59, 1015, 10.1097/00007890-199504150-00017 Carreras, 1993, Transjugular liver biopsy in BMT, Bone Marrow Transplant, 11, 21 Iqbal, 1996, Laparoscopic liver biopsy to evaluate hepatic dysfunction in patients with hematologic malignancies: a useful tool to effect changes in management, Bone Marrow Transplant, 17, 655 Salat, 1997, Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation, Blood, 89, 2184, 10.1182/blood.V89.6.2184 Richardson, 2002, Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome, Blood, 100, 4337, 10.1182/blood-2002-04-1216 Jacobson, 1990, Increased lung uptake on technetium-99m-sulfur colloid liver-spleen scans in patients with hepatic venoocclusive disease following bone marrow transplantation, J Nucl Med, 31, 372 Rio, 1993, N-terminal peptide of type III procollagen: a marker for the development of hepatic venoocclusive disease after BMT and a basis for determining the timing of prophylactic heparin, Bone Marrow Transplant, 11, 471 Baglin, 1990, Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA), Bone Marrow Transplant, 5, 439 Bearman, 1992, Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation, Blood, 80, 2458, 10.1182/blood.V80.10.2458.2458 Simpson, 1994, Successful treatment of veno-occlusive disease with recombinant tissue plasminogen activator in a patient requiring peritoneal dialysis, Bone Marrow Transplant, 14, 635 Leahey, 1996, Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients, Bone Marrow Transplant, 17, 1101 Bearman, 1997, Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients, Blood, 89, 1501, 10.1182/blood.V89.5.1501 Schriber, 1999, Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation, Bone Marrow Transplant, 24, 1311, 10.1038/sj.bmt.1702069 Fogteloo, 1993, Successful treatment of veno-occlusive disease of the liver with urokinase in a patient with non-Hodgkin's lymphoma, LeukemiA, 7, 760 Richardson, 1998, Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population, Blood, 92, 737 Chopra, 2000, Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study, Br J Haematol, 111, 1122, 10.1046/j.1365-2141.2000.02475.x Ringdén, 2000, N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation, Bone Marrow Transplant, 25, 993, 10.1038/sj.bmt.1702387 Khoury, 2000, Does early treatment with high-dose methylprednisolone alter the course of hepatic regimen-related toxicity?, Bone Marrow Transplant, 25, 737, 10.1038/sj.bmt.1702209 Sayer, 2002, Hepatic veno-occlusive disease (VOD) with complete occlusion of liver venules after tandem autologous stem cell transplantation—successful treatment with high-dose methylprednisolone and defibrotide, J Cancer Res Clin Oncol, 128, 148, 10.1007/s00432-001-0316-z Higashigawa, 1995, Successful treatment of an infant with veno-occlusive disease developed after allogeneic bone marrow transplantation by tissue plasminogen activator, heparin and prostaglandin E1, Leuk Res, 19, 477, 10.1016/0145-2126(95)00009-D Schlegel, 1998, Hepatic veno-occlusive disease in pediatric stem cell recipients: successful treatment with continuous infusion of prostaglandin E1 and low-dose heparin, Ann Hematol, 76, 37, 10.1007/s002770050358 Goringe, 1998, Glutamine and vitamin E in the treatment of hepatic veno-occlusive disease following high-dose chemotherapy, Bone Marrow Transplant, 21, 829, 10.1038/sj.bmt.1701172 Nattakom, 1995, Use of vitamin E and glutamine in the successful treatment of severe veno-occlusive disease following bone marrow transplantation, Nutr Clin Pract, 10, 16, 10.1177/011542659501000116 Terasaki, 1994, Hemodynamics and hepatic energy metabolism in canine model of acute hepatic venous occlusion with mesocaval shunt, Eur Surg Res, 26, 19, 10.1159/000129314 Azoulay, 2000, Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation, Bone Marrow Transplant, 25, 987, 10.1038/sj.bmt.1702386 Fried, 1996, Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation, Hepatology, 24, 588, 10.1002/hep.510240321 Rapoport, 1991, Orthotopic liver transplantation for life-threatening venoocclusive disease of the liver after allogeneic bone marrow transplant, Bone Marrow Transplant, 8, 421 Dowlati, 1995, Hepatic rejection after orthotopic liver transplantation for hepatic veno-occlusive disease or graft-versus-host disease following bone marrow transplantation, Transplantation, 60, 106, 10.1097/00007890-199507150-00020 Tefferi, 2001, Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation, Bone Marrow Transplant, 28, 997, 10.1038/sj.bmt.1703267 Bearman, 1990, A pilot study of continuous infusion heparin for the prevention of hepatic venoocclusive disease after bone marrow transplantation, Bone Marrow Transplant, 5, 407 Attal, 1992, Prevention of hepatic venoocclusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial, Blood, 79, 2834, 10.1182/blood.V79.11.2834.bloodjournal79112834 Or, 1996, Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients, Transplantation, 61, 1067, 10.1097/00007890-199604150-00014 Or, 1996, Low molecular weight heparin stimulates megakaryocytopoiesis in bone-marrow transplantation patients, Am J Hematol, 53, 46, 10.1002/(SICI)1096-8652(199609)53:1<46::AID-AJH11>3.0.CO;2-1 Essell, 1998, Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation: a randomized, double-blind, placebo-controlled trial, Ann Intern Med, 128, 975, 10.7326/0003-4819-128-12_Part_1-199806150-00002 Ohashi, 2000, The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation, Am J Hematol, 64, 32, 10.1002/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.0.CO;2-N Park, 2002, A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation, Bone Marrow Transplant, 29, 137, 10.1038/sj.bmt.1703342 Gluckman, 1990, Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation, Br J Haematol, 74, 277, 10.1111/j.1365-2141.1990.tb02583.x Bearman, 1993, A phase I/II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation, Br J Haematol, 84, 724, 10.1111/j.1365-2141.1993.tb03152.x Attal, 1993, Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial, Blood, 82, 732, 10.1182/blood.V82.3.732.732 Clift, 1993, A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation, Blood, 82, 2025, 10.1182/blood.V82.7.2025.2025 Brown, 1998, Parenteral glutamine protects hepatic function during bone marrow transplantation, Bone Marrow Transplant, 22, 281, 10.1038/sj.bmt.1701321